Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 213Myelodysplastic Syndromes 82Leukemia 44Leukemia, Myelomonocytic, Chronic 35Recurrence 16Myeloproliferative Disorders 15Neoplasm, Residual 10Lymphoma, T-Cell, Peripheral 10Leukemia, Biphenotypic, Acute 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Large B-Cell, Diffuse 7Anemia, Refractory, with Excess of Blasts 7Primary Myelofibrosis 6Lymphoma, Non-Hodgkin 6Hodgkin Disease 6Congenital Abnormalities 6Lymphoma, T-Cell 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Monocytic, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Polycythemia Vera 4Pancreatic Neoplasms 4Multiple Myeloma 4Lymphoma, Follicular 4Lymphoma, Extranodal NK-T-Cell 4Leukemia, Myeloid 4

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × Azacitidine × Clear all
NCT01292083 2014-02-06

Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

University of Southern California

Phase NA Withdrawn
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡